Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | S100A4 | P26447 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15624258 | 1.00 | ACHE (0.42) | ACHEMEN1KMT2AS100A4POLB | |
| SCHEMBL12112154 | 0.86 | GPR3 (0.40) | ACHEMEN1KMT2AS100A4POLB | |
| SCHEMBL15245116 | 0.85 | MEN1 (0.55) | ACHEMEN1KMT2AS100A4POLB | |
| SCHEMBL17262530 | 0.80 | ACHE (0.38) | ACHEMEN1KMT2AS100A4POLB | |
| SCHEMBL11779406 | 0.77 | ACHE (0.36) | ACHEMEN1KMT2AS100A4POLB | |
| SCHEMBL14665269 | 0.77 | MAPT (0.45) | ACHEMEN1KMT2AHTR2BHTR2A | |
| SCHEMBL18402943 | 0.77 | ALDH1A1 (0.38) | ACHEMEN1KMT2AS100A4POLB | |
| SCHEMBL11547366 | 0.77 | CYP1A2 (0.45) | ACHEMEN1KMT2AHTR2BLMNA | |
| SCHEMBL27513787 | 0.76 | EDNRB (0.44) | MEN1KMT2APOLBLMNACYP1A2 | |
| SCHEMBL21197721 | 0.74 | MAPK1 (0.41) | ACHEMEN1KMT2AS100A4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819662-B1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2019-04-10 | — | — | EP | disclosed |
| US-9552457-B2 | Reprogramming effector protein interactions to correct epigenetic defects in cancer | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-01-24 | — | — | US | disclosed |
| US-9552457-B2 | Reprogramming effector protein interactions to correct epigenetic defects in cancer | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-01-24 | — | — | US | disclosed |
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-06-04 | — | — | US | disclosed |
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-06-04 | — | — | US | disclosed |
| US-8969624-B2 | Cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions | EVONIK DEGUSSA GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969624-B2 | Cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions | EVONIK DEGUSSA GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969624-B2 | Cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions | EVONIK DEGUSSA GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2057174-B1 | NEW CYCLOPENTADIENYL, INDENYL OR FLUORENYL SUBSTITUTED PHOSPHINE COMPOUNDS AND THEIR USE IN CATALYTIC REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| EP-2057174-B1 | NEW CYCLOPENTADIENYL, INDENYL OR FLUORENYL SUBSTITUTED PHOSPHINE COMPOUNDS AND THEIR USE IN CATALYTIC REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| WO-2008025673-A1 | NEW CYCLOPENTADIENYL, INDENYL OR FLUORENYL SUBSTITUTED PHOSPHINE COMPOUNDS AND THEIR USE IN CATALYTIC REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2008-03-06 | — | — | WO | disclosed |
| EP-1894938-A1 | New cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions | Evonik Degussa GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1894938-A1 | New cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions | Evonik Degussa GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-0798306-B1 | Substituted indenyl unbridged metallocenes | PHILLIPS PETROLEUM CO (US) | 2002-05-22 | — | — | EP | disclosed |
| US-6037427-A | UNBRIDGED METALLOCENE CATALYSTS USED IN COMBINATION WITH SUITABLE COCATALYST FOR THE POLYMERIZATION OF OLEFINIC MONOMERS | SCHMID CLAUDIA (DE) | 2000-03-14 | — | — | US | disclosed |
| EP-0707013-B1 | CATALYST FOR PRODUCING STYRENE POLYMER AND PROCESS FOR PRODUCING STYRENE POLYMER USING THE SAME | IDEMITSU KOSAN CO (JP) | 1999-11-24 | — | — | EP | disclosed |
| US-5780659-A | ADDITION POLYMERIZATION CATALYSTS | PHILLIPS PETROLEUM COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
| US-5747614-A | Catalyst for producing sytrenic polymer and process for producing sytrenic polymer by using same | IDEMITSU KOSAN CO., LTD. (JP) | 1998-05-05 | — | — | US | disclosed |
| EP-0798306-A1 | Substituted indenyl unbridged metallocenes | PHILLIPS PETROLEUM COMPANY (US) | 1997-10-01 | — | — | EP | disclosed |
| EP-0707013-A1 | CATALYST FOR PRODUCING STYRENE POLYMER AND PROCESS FOR PRODUCING STYRENE POLYMER USING THE SAME | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1996-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | CBX2, BPTF, CBX4 | ACHE 4503/4885MEN1 3248/4885KMT2A 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.